References
- SimonsFEAnaphylaxis: recent advances in assessment and treatmentJ Allergy Clin Immunol2009124462563619815109
- SimonsFEAnaphylaxisJ Allergy Clin Immunol20101252 Suppl 2S161S18120176258
- SimonsFESheikhAAnaphylaxis: the acute episode and beyondBMJ2013346f60223403828
- SclarDAEconomic burden of anaphylaxis in the United StatesPoster presented at: Eastern Allergy ConferenceMay 31-June 3, 2012Palm Beach, FL, USA
- SimonsFEGuXSimonsKJEpinephrine absorption in adults: intramuscular versus subcutaneous injectionJ Allergy Clin Immunol2001108587187311692118
- PumphreyRSLessons for management of anaphylaxis from a study of fatal reactionsClin Exp Allergy20003081144115010931122
- Center for Drug Evaluation and ResearchApplication Number: 201739Orig1s000Clinical Pharmacology and Biopharmaceutics Review(s) Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201739Orig1s000ClinPharmR.pdfAccessed February 1, 2013
- Center for Drug Evaluation and ResearchApplication Number: 201739Orig1s000Medical Review(s) Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201739Orig1s000MedR.pdfAccessed February 1, 2013
- HaidarSHDavitBChenMLBioequivalence approaches for highly variable drugs and drug productsPharm Res200825123724117891552
- EdwardsESGunnRSimonsFEREpinephrine 0.3 mg bioavailability following a single injection with a novel epinephrine auto-injector, e-cue™, in healthy adults, with reference to a single injection using EpiPen 0.3 mg [abstract]J Allergy Clin Immunol2012129Suppl 2AB179 Available from: http://download.journals.elsevierhealth.com/pdfs/journals/0091-6749/PIIS009167491102197X.pdfAccessed February 1, 2012